Molecular pathogenesis of pancreatic cancer;Molekulární patogeneze karcinomu pankreatu

Ceska a Slovenska Gastroenterologie a Hepatologie

Volumn 63, Issue 2, 2009, Pages 58-64

  Hucl, Tomáš ^a   Špičák, Julius ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Fanconi anemia; Pancreatic cancer; Pathogenesis

Indexed keywords

BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; K RAS PROTEIN; PROTEIN KINASE LKB1; PROTEIN P53; SMAD4 PROTEIN;

ARTICLE; CANCER CONTROL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CANCER MORTALITY; CARCINOGENESIS; EARLY DIAGNOSIS; FANCONI ANEMIA; FEMALE; GENE MUTATION; GENETIC RISK; HISTOLOGY; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MALE; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; PANCREAS CANCER; PANCREAS CARCINOMA; PATIENT IDENTIFICATION; PROGNOSIS;

EID: 67149120750     PISSN: 1213323X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Gold EB. Epidemiology of and risk factors for pancreatic cancer. Surg Clin North Am 1995; 75: 819-843.
2. Hulst SPL. Zur kenntnis der Genese des Adenokarzi- noms und Karzinoms des Pankreas. Trans. T. van Heek and V. Koopman. Vircdhows Arch B 1905; 180: 288-316.
3. Hruban RH, Adsaz NV, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasia: A new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001; 25: 579-586.
4. Hruban RH, Maitra A, Kern SE, et al. Precursors to pancreatic cancer. Gastroenterol Clin North Am 2007; 36: 831-849.
5. Kern SE. Advances from genetic clues in pancreatic cancer. Curr Opin One 1998; 10: 74-80.
6. Hruban RH, Wilentz R, Kern SE. Genetic progression in the pancreatic ducts. Am J Pathol 2000; 156: 1821-1825.
7. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001; 25: 579-586.
8. Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg 2004; 239: 788-797.
9. Hruban RH, Maitra A, Kern SE, Goggins M. Precursors to pancreatic cancer. Gastroenterol Clin North Am 2007; 36: 831-849.
10. Bassi C, Sarr MG, Lillemoe KD, et al. Natural history of intraductal papillary mucinous neoplasms (IPMN): current evidence and implications for management. J Gastrointest Surg 2008; 12: 645-650.
11. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pankreas contain mutant c-Kras genes. Cell 1988; 53: 549-554.
12. Wilentz RE, Goggins M, Redston M, et al. Genetic, immunohistochemical, and clinical feature sof medullary carcinomas of the pancreas: a newly described and characterized entity. Am J Pathol 2000; 156: 1641-1651.
13. Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the pl6 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994; 8: 27-32.
14. Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb/pl6 tumor-supressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997; 57: 3126-3130.
15. Pellegata S, Sessa F, Renault B, et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and non- ductal tumors progress through different genetic lesions. Cancer Res 1994; 54: 1556-1560.
16. Rozenblum E, Schutte M, Goggins M, et al. Tumor- supressive pathways in pancreatic carcinoma. Cancer Res 1997; 57: 1731-1734.
17. Hanh SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350-353.
18. Jones JB, Song JJ, Hempen PM, et al. Detection of mitochondrial DNA mutations in pancreatic cancer offers a mass-ive advantage over detection of nuclear DNA mutations. Cancer Res 2001; 61:1299-1304.
19. Hahn SA, Seymour AB, Hoque ATMS, et al. Allelo- type of pancreatic adenocarcinoma using a xenograft model. Cancer Res 1995; 55: 4670-4675.
20. Goggins M, Shekher M, Turnacioglu K, et al. Genetic alterations of the TGF beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 1998; 58: 5329-5332.
21. Su GH, Bansal R, Montgomery E, et al. ACVR1B (ALK4) gene mutations in pancreatic carcinoma. Proc Natl Acad Sci USA 2001; 98: 3254-3257.
22. Su GH, Hruban RH, Bansal RK, et al. Germline and static mutations of the STK11/LKB1 Peutz- Jeghers gene in pancreatic and biliary cancers. Am J Pathol 1999; 154: 1835-1840.
23. Ruggeri B, Zhang SY, Caamano J, et al. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and RB-1 tumor- supressor genes. Oncogene 1992; 7:1503-1511.
24. Su GH, Hilgers W, Shekher M, et al. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor-supressor gene. Cancer Res 1998; 58: 2339-2342.
25. Kern SE, Hruban RH, Hidalgo M, et al. An introduction to pancreatic adenocarcinoma genetics, pathology and therapy. Cancer Biol Ther 2002; 1:607-613.
26. Calhoun ES, Jones JB, Ashfaq R, et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol 2003; 163: 1255-1260.
27. Hempen PM, Kurpad H, Calhoun ES, et al. A double missense variation of the BUB1 gene and a defective mitotic spindle checkpoint in the pancreatic cancer cell line Hs766T. Hum Mutat 2003; 21: 445.
28. van der Heijden MS, Yeo CJ, Hruban RH, et al. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 2003; 15: 2585-2588.
29. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996; 56:5360-5364.
30. Maitra A, Kern SE, Hruban RH. Molecular pathogenesis of pancreatic cancer. Best Pract Res clin Gastroenterol 2006; 20: 211-226.
31. Wallrapp C, Muller-Pillasch F, Solinas-Toldo S, et al. Characterization of a high copy number amplification at 6q24 in pancreatic cancer identifies c-MYB as a candidate oncogene. Cancer Res 1997; 57:3135-3139.
32. Ruggeri BA, Huang L, Wood M, et al. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog 1998; 21: 81-86.
33. Van Heek NT, Meeker AK, Kern SE, et al. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol 2002; 161:1541-1547.
34. Caldas C, Hahn SA, Hruban RH, et al. Detection of K-ras mutations in the stool of patiens with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994; 54: 3568-3573.
35. Moskaluk CA, Hruban RH, Kern SE. pl6 and K-ras mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 1997; 57: 2140-2143.
36. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000; 60: 2002-2005.
37. Lynch HT, Smyrk T, Kern SE, et al. Familial pancreatic cancer: a review. Semin Oncol 1996; 23: 251-275.
38. Klein AP, Hruban RH, Brune KA, et al. Familial pancreatic cancer. Cancer J 2001; 7: 266-273.
39. Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002; 62:3789-3793.
40. Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with pl6INK4 mutations. Ne Engl J Med 1995; 333: 970-974.
41. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000; 119: 1447-1453.
42. Lynch HT, Voorhees GH, Lanspa SJ, et al. Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. Br J Cancer 1985: 52: 271- 273.
43. Whitcomb DC, Gorry MC, Preston RA, et al. Hereditary pankreatitis is caused by a station in the cationic trypsinogen gene. Nature Genet 1996; 14:141-145.
44. Lowenfels AB, Maisonneuve P, DiMagno EP, et al. Hereditary pankreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. Journal of the National Cancer Institute 1997; 89: 442-446.
45. Ryu B, Jones J, Blades NJ, et al. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res 2002; 62: 819-826.
46. Hucl T, Brody JR, Gallmeier E, et al. High cancer- specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhacer factor dependent MCAT motif. Cancer Res 2007; 67: 9055-9065.
47. D'Andrea AD, Grompe M. The Fanconi anaemia/ BRCA pathway. Nat Rev Cancer 2003; 3: 23-34.
48. Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003; 9: 568-574.
49. Howlett NG, Tanigushi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002; 297: 606-609.
50. van der Heijden MS, Brody JR, Dezentje DA, et al. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 2005; 11: 7508-7515.
51. Gallmeier E, Kern SE. Targeting Fanconi anemia/ BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models. Clin Cancer Res 2007; 13: 4-10.
52. Kris MG, Natall RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-2158.
53. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
54. Cohen EE, Lingen MW, Martin LE. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res 2005;11:8105-8108.
55. Kwak EL, Jankowski J, Thayer SP. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 2006; 12: 4283-4287.
56. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. J Clin Oncol 2007; 25: 1960-1966.
57. Thomas AM, Santarsiero LM, Lutz ER, et al. Meso- thelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004; 200: 297-306.